Current Edition


M&A anxiety, Roche’s comeback plan and Vir’s omicron moment

The second day of the J.P. Morgan Healthcare Conference, much like the first, didn’t include the type of market-moving acquisitions or announcements that might break …

Continue Reading →

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

In some ways, AstraZeneca’s COVID-19 response has been as good as any in the biopharmaceutical industry. The British drugmaker licensed and developed an effective COVID-19 …

Continue Reading →

Avacta appoints Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division

Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces …

Continue Reading →

Trade Idea: Biopharmaceutical Endocyte Hits 4-Year High on Earnings

ECYT lives squarely in small-cap territory. And that’1018s not a bad thing in 2018. On a year-to-date basis, the small-cap focused Russell 2000 Index has …

Continue Reading →

Biopharmaceuticals Market Strongly guided by Companies like ABBVIE, AMGEN, BRISTOL

The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the …

Continue Reading →

Putting the Technicals Into Perspective For Sino Biopharmaceutical ADR (SBHMY)

Investors have placed Sino Biopharmaceutical ADR (SBHMY) shares on watch as the Aroon Up indicator has moved above 70, indicating that there is strong upward …

Continue Reading →